Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Tumor immunotherapy directed at PD-1.

Ribas A.

N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2. No abstract available.

PMID:
22658126
2.

Progress in immunotherapy of cancer.

Rook AH, Raphael BA.

N Engl J Med. 2012 Sep 20;367(12):1168; author reply 1168. doi: 10.1056/NEJMc1208946. No abstract available.

3.

Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Daskivich TJ, Belldegrun A.

Eur Urol. 2015 Apr;67(4):816-7. doi: 10.1016/j.eururo.2014.12.052. No abstract available.

PMID:
25765212
4.

Programmed death protein 1 inhibitors making inroads in multiple cancers.

Brower V.

J Natl Cancer Inst. 2015 May 9;107(5). pii: djv141. doi: 10.1093/jnci/djv141. Print 2015 May. No abstract available.

PMID:
25957444
5.

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

Kelderman S, Schumacher TN, Kvistborg P.

Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.

6.

Nivolumab shows clinical activity in Hodgkin's lymphoma.

Bagcchi S.

Lancet Oncol. 2015 Mar;16(3):e108. doi: 10.1016/S1470-2045(15)70024-0. Epub 2015 Jan 30. No abstract available.

PMID:
25639369
7.

Release the hounds! Activating the T-cell response to cancer.

Sznol M, Longo DL.

N Engl J Med. 2015 Jan 22;372(4):374-5. doi: 10.1056/NEJMe1413488. Epub 2014 Dec 6. No abstract available.

PMID:
25482238
8.

Haematological cancer: PD-1 blockade: opening the door to attack.

Hutchinson L.

Nat Rev Clin Oncol. 2015 Feb;12(2):65. doi: 10.1038/nrclinonc.2014.227. Epub 2014 Dec 23. No abstract available.

PMID:
25533946
9.

PD-1-targeted immunotherapy: recent clinical findings.

Brahmer JR.

Clin Adv Hematol Oncol. 2012 Oct;10(10):674-5. No abstract available.

PMID:
23187774
10.

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.

Henick BS, Herbst RS, Goldberg SB.

Expert Opin Ther Targets. 2014 Dec;18(12):1407-20. doi: 10.1517/14728222.2014.955794. Epub 2014 Oct 21. Review.

PMID:
25331677
11.

[Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials].

Penel N.

Bull Cancer. 2016 Oct;103(10):811-812. doi: 10.1016/j.bulcan.2016.08.005. Epub 2016 Oct 4. French. No abstract available.

PMID:
27712832
12.

Melanoma: immune checkpoint blockade story gets better.

Bhatia S, Thompson JA.

Lancet. 2014 Sep 20;384(9948):1078-9. doi: 10.1016/S0140-6736(14)61140-5. Epub 2014 Jul 15. No abstract available.

PMID:
25034863
13.

Immuno-oncology moves beyond PD-1.

Sheridan C.

Nat Biotechnol. 2015 Jul;33(7):673-5. doi: 10.1038/nbt0715-673. No abstract available.

PMID:
26153987
14.

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL.

Clin Cancer Res. 2013 Jan 15;19(2):462-8. doi: 10.1158/1078-0432.CCR-12-2625. Epub 2012 Nov 20.

15.

American Association of Cancer Research Showcases Immunotherapy Advances.

Brower V.

J Natl Cancer Inst. 2015 Aug 4;107(8). pii: djv231. doi: 10.1093/jnci/djv231. Print 2015 Aug. No abstract available.

16.

PD-1 inhibitors effective in hodgkin lymphoma.

[No authors listed]

Cancer Discov. 2015 Feb;5(2):102-3. doi: 10.1158/2159-8290.CD-NB2015-002. Epub 2015 Jan 9. No abstract available.

17.

Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1.

Chanal J, Kramkimel N, Guegan S, Moguelet P, Fourchotte V, Avril MF.

J Low Genit Tract Dis. 2016 Jan;20(1):e4-5. doi: 10.1097/LGT.0000000000000168. No abstract available.

PMID:
26704337
18.

Utilisation des inhibiteurs de PD-1 dans les hémopathies lymphoïdes.

Bounaix L, Bendouda M, Bay JO, Lemal R.

Bull Cancer. 2016 Nov;103 Suppl 1:S160-S163. doi: 10.1016/S0007-4551(16)30374-5. Review. French.

PMID:
28057180
19.

New checkpoint inhibitors ride the immunotherapy tsunami.

Mullard A.

Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066. No abstract available.

PMID:
23812256
20.

Targeting Programmed Cell Death 1 in Ovarian Cancer.

Homicsko K, Coukos G.

J Clin Oncol. 2015 Dec 1;33(34):3987-9. doi: 10.1200/JCO.2015.63.7785. Epub 2015 Oct 26. No abstract available.

PMID:
26503205

Supplemental Content

Support Center